Takeda Accelerates Lung‑Cancer Therapy IBI363, Boosting Oncology ROI & M&A Appeal
Takeda partners on IBI363, a lung‑cancer therapy, to hit unmet NSCLC needs with a 3‑year payback and 150% ROI, boosting its oncology pipeline and M&A prospects.
4 minutes to read